Results include $1.2 billion of sales from rare disease products, driven by TEPEZZA, KRYSTEXXA, UPLIZNA, and TAVNEOS. Earnings reflect acquisition-related costs related to the Horizon acquisition.
Glioblastoma Multiforme Treatment Market size is expected to reach USD 4.7 Billion by 2033 from USD 2.2 Billion in 2023, at a CAGR of 8.1%. Lawrence John Prudour +91 91308 55334 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results